Skip to main content
. 2024 Jan 31;113(10):1451–1462. doi: 10.1007/s00392-024-02376-8

Table 1.

Baseline characteristics

Stroke group Non-stroke group p-value*
Total cohort, n (% of all patients) 137 (21.5) 501 (78.5) -
Male sex, n (%) 86 (62.8) 304 (60.7) 0.66
Age [years], median (IQR) 76 (72; 80) 77 (73; 82) 0.09
Body mass index [kg/m2], median (IQR) 26.4 (24.1; 29.8) 26.8 (24.2; 30.2) 0.61
CHA2DS2-VASc score, mean ± SD 5.9 ± 1.3 4.1 ± 1.4 < 0.001
HAS-BLED score, mean ± SD 4.6 ± 1.0 3.7 ± 1.1  < 0.001
Arterial hypertension, n (%) 132 (96.4) 461 (92.0) 0.08
Diabetes mellitus, n (%) 53 (38.7) 164 (32.7) 0.19
Congestive heart failure, n (%) 33 (24.1) 139 (27.7) 0.39
Coronary heart disease, n (%) 58 (42.3) 234 (46.7) 0.36
eGFR [MDRD], median (IQR) 65.9 (41.8; 86.0) 61.0 (41.7; 78.3) 0.17
Pattern of AF, each n (%)
  • Paroxysmal 58 (42.3) 216 (43.1) 0.87
  • Persistent 23 (16.8) 92 (18.4) 0.67
  • Permanent 56 (40.9) 193 (38.5) 0.62
Prior pulmonary vein isolation, n (%) 6 (4.4) 11 (2.2) 0.16
Indication for LAAO, each n (%)
  • Prior bleeding 97 (70.8) 410 (81.8) 0.005
  • Contraindication to OAC 28 (20.4) 93 (18.6) 0.62
  • Labile INR 12 (8.8) 42 (8.4) 0.89
  • OAC incompliance 8 (5.8) 25 (5.0) 0.69
  • Patient’s preference 30 (21.9) 131 (26.1) 0.31
  • Other reason 15 (10.9) 43 (8.6) 0.39
Ejection fraction [%], median (IQR) 60 (50; 60) 60 (50; 60) 0.75
Ejection fraction ≤ 40%, n (%) 14 (10.7) 60 (12.3) 0.61
LA diameter [mm], median (IQR)** 47 (44; 50) 48 (44; 52) 0.223
LA area [cm2], median (IQR)** 30 (21; 44) 26 (20; 32) 0.21

* Tested by Pearson’s chi-squared or Mann–Whitney-Wilcoxon test; bold indicates ≤ 0.05; more than one item could occur in the same patient; **these two measurements could be documented alternatively; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; IQR, interquartile range; LA(AO), left atrial (appendage occlusion); MDRD, Modification of Diet in Renal Disease [equation]; OAC, oral anticoagulation; SD, standard deviation